Core Viewpoint - Kamada Ltd. reported strong financial results for the second quarter and first half of 2025, with significant revenue growth and increased adjusted EBITDA, leading to an upward revision of its annual guidance for both adjusted EBITDA and total revenues [2][4][9]. Financial Performance - Total revenues for the first half of 2025 were $88.8 million, an 11% increase year-over-year, with second-quarter revenues at $44.8 million, up 5% from $42.5 million in the same quarter of 2024 [4][5][11]. - Adjusted EBITDA for the first half of 2025 was $22.5 million, reflecting a 35% increase year-over-year, with a margin of 25% on revenues; second-quarter adjusted EBITDA was $10.9 million, up 20% year-over-year [4][11]. - Net income for the first half of 2025 was $11.3 million, or $0.19 per diluted share, a 67% increase compared to $6.8 million, or $0.12 per diluted share, in the first half of 2024 [11][20]. Operational Highlights - The company received FDA approval for its plasma collection center in Houston, Texas, which has an annual collection capacity of approximately 50,000 liters of plasma and is expected to contribute $8 million to $10 million in annual revenue at full capacity [2][12][17]. - Kamada continues to focus on expanding its plasma collection operations and is ramping up collection at its three Texas-based centers [2][12]. Strategic Outlook - Based on the strong performance in the first half of 2025, Kamada has increased its annual adjusted EBITDA guidance to a range of $40 million to $44 million and reiterated its full-year revenue guidance of $178 million to $182 million [2][9]. - The company is committed to investing in strategic growth pillars, including organic growth, business development, and M&A opportunities, to enhance its portfolio of marketed products [2][15][17].

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplement to its existing Biologics License Application (BLA) for Kamada Plasma's collection center in Houston, TX. The approval was obtained followi ...

Kamada Ltd. (the "Company") is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company's strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialt ...

Core Viewpoint - Kamada Ltd. continues its operations and manufacturing in Israel despite evolving circumstances in the Middle East, ensuring that the global availability of its products remains uninterrupted [1][2]. Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3]. - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®, along with other proprietary products and biosimilars [3]. - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3]. Business Continuity and Operations - The company is focused on business continuity and has sufficient product levels available through distribution centers outside Israel, despite temporary disruptions due to the closing of Israeli airspace [2][4]. - Kamada is actively monitoring the situation and prioritizing the well-being of its employees while ensuring that client demands are met without shortages [2][4]. Growth Strategy - Kamada's growth strategy is built on four pillars: organic growth through commercialization, securing new business development opportunities, expanding plasma collection operations, and advancing product candidates in development [3]. - The company operates three plasma collection centers in the United States to support revenue growth and meet increasing demand for hyper-immune plasma [3]. - The lead product candidate is Inhaled AAT, currently progressing through the InnovAATe clinical trial, a pivotal Phase 3 trial [3].

REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025. "Results for the first quarter of 2025 were in line with our expectations and consistent with the strong operational and commercial performance we generated ...

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the first quarter ending March 31, 2025, prior to the opening of U.S. financial markets on May 14, 2025 [1] - An investment community conference call will be held on the same day at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and M&A to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and meet increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]